These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 9820177

  • 1. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.
    Grundy RG, Pritchard J, Scambler P, Cowell JK.
    Br J Cancer; 1998 Nov; 78(9):1181-7. PubMed ID: 9820177
    [Abstract] [Full Text] [Related]

  • 2. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M.
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [Abstract] [Full Text] [Related]

  • 3. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
    Mason JE, Goodfellow PJ, Grundy PE, Skinner MA.
    J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
    [Abstract] [Full Text] [Related]

  • 4. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
    Safford SD, Goyeau D, Freemerman AJ, Bentley R, Everett ML, Grundy PE, Skinner MA.
    Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
    [Abstract] [Full Text] [Related]

  • 5. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
    Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC.
    Cancer Res; 1994 May 01; 54(9):2331-3. PubMed ID: 8162576
    [Abstract] [Full Text] [Related]

  • 6. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM, National Wilms Tumor Study Group.
    J Clin Oncol; 2005 Oct 10; 23(29):7312-21. PubMed ID: 16129848
    [Abstract] [Full Text] [Related]

  • 7. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK, Brown KW, Berry PJ.
    Am J Pathol; 1998 Sep 10; 153(3):991-1000. PubMed ID: 9736048
    [Abstract] [Full Text] [Related]

  • 8. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.
    Mol Cancer Res; 2005 Sep 10; 3(9):493-502. PubMed ID: 16179496
    [Abstract] [Full Text] [Related]

  • 9. Loss of heterozygosity at 7p in Wilms' tumour development.
    Powlesland RM, Charles AK, Malik KT, Reynolds PA, Pires S, Boavida M, Brown KW.
    Br J Cancer; 2000 Jan 10; 82(2):323-9. PubMed ID: 10646884
    [Abstract] [Full Text] [Related]

  • 10. Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.
    Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K, Children's Cancer and Leukaemia Group (CCLG).
    Eur J Cancer; 2009 Mar 10; 45(5):819-26. PubMed ID: 19231157
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P, Telzerow P, Moksness J, Breslow NE.
    Med Pediatr Oncol; 1996 Nov 10; 27(5):429-33. PubMed ID: 8926924
    [Abstract] [Full Text] [Related]

  • 12. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
    Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M.
    Genes Chromosomes Cancer; 2007 Feb 10; 46(2):163-70. PubMed ID: 17099873
    [Abstract] [Full Text] [Related]

  • 13. Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.
    Bu Q, He H, Fan D, Lyu J, Pan Z, You H.
    Pathol Res Pract; 2018 Nov 10; 214(11):1772-1777. PubMed ID: 30143352
    [Abstract] [Full Text] [Related]

  • 14. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE, Noh OK, Lee Y, Choi HS, Han JW, Hahn SM, Lyu CJ, Lee JW, Yoo KH, Koo HH, Jeong SY, Sung KW.
    Cancer Res Treat; 2020 Apr 10; 52(2):438-445. PubMed ID: 31505910
    [Abstract] [Full Text] [Related]

  • 15. Molecular analysis of E-cadherin and cadherin-11 in Wilms' tumours.
    Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Becker I, Atkinson M, Gessler M, Höfler H.
    J Pathol; 2000 Jun 10; 191(2):162-9. PubMed ID: 10861576
    [Abstract] [Full Text] [Related]

  • 16. A third Wilms' tumor locus on chromosome 16q.
    Maw MA, Grundy PE, Millow LJ, Eccles MR, Dunn RS, Smith PJ, Feinberg AP, Law DJ, Paterson MC, Telzerow PE.
    Cancer Res; 1992 Jun 01; 52(11):3094-8. PubMed ID: 1317258
    [Abstract] [Full Text] [Related]

  • 17. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
    Cowell JK, Groves N, Baird P.
    Br J Cancer; 1993 Jun 01; 67(6):1259-61. PubMed ID: 8390282
    [Abstract] [Full Text] [Related]

  • 18. Identification of a new WT1 mutation in a sporadic Wilms' tumour.
    Santos AC, Boavida MG, Costa A, Osorio-Almeida L.
    Biochim Biophys Acta; 1998 Aug 14; 1407(2):109-13. PubMed ID: 9685601
    [Abstract] [Full Text] [Related]

  • 19. The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene.
    Rahman N, Arbour L, Tonin P, Baruchel S, Pritchard-Jones K, Narod SA, Stratton MR.
    Oncogene; 1997 Jun 26; 14(25):3099-102. PubMed ID: 9223674
    [Abstract] [Full Text] [Related]

  • 20. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M, Bahanassy A, Samir A, Hafez H.
    Pediatr Hematol Oncol; 2015 Jun 26; 32(8):548-56. PubMed ID: 26390800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.